论文部分内容阅读
目的观察并比较替米沙坦单用或与苯磺酸氨氯地平联用治疗原发性原发性高血压临床疗效及安全性。方法选取我院心内科2010年8月至2012年1月收治原发性原发性高血压患者160例,采用随机数字表法分为两组,其中单用组102例,单纯采用替米沙坦口服治疗,80mg/d;联合治疗组106例,在单用组治疗基础之上,加用苯磺酸氢氯地平口服治疗,首周剂量为2.5mg/d,如症状改善不明显则可加量至5mg/d,疗程均为8周;疗程结束后比较两组患者治疗总有效率,治疗前后舒张压、收缩压改善情况以及不良反应发生率、严重情况等。结果 ;联合治疗组临床治疗总有效率明显高于单用组,组间比较差异有统计学意义(P<0.05);联合治疗组和单用组与治疗前相比,治疗后舒张压、收缩压均有显著下降,且联合治疗组收缩压,舒张压改善情况均明显优于单用组,组间比较差异有统计学意义(P<0.05);联合治疗组治疗过程中不良反应发生率为11.3%;单用组治疗过程中不良反应发生率为16.3%;联合治疗组不良反应发生率明显低于单用组,组间比较差异有统计学意义(P<0.05)。同时联合治疗组与单用组治疗前后血尿常规及肝肾功能实验室指标组间、组内比较亦无明显变化(P>0.05)。结论与替米沙坦单用治疗相比,替米沙坦与苯磺酸氨氯地平联用治疗原发性原发性高血压能够更有效改善临床症状,控制血压水平,且无严重不良反应出现。
Objective To observe and compare the clinical efficacy and safety of telmisartan alone or in combination with amlodipine besylate in the treatment of essential hypertension. Methods A total of 160 patients with primary essential hypertension were enrolled in our hospital from August 2010 to January 2012. The patients were divided into two groups randomly, Oral oral treatment, 80mg / d; combined treatment group of 106 patients on the basis of single-group therapy, plus oral treatment with hydrochlobenzene besylate oral dose of 2.5mg / d, if the symptoms were not significantly improved Dosage to 5mg / d, the course of treatment were 8 weeks; after treatment, the total effective rate of two groups were compared, before and after treatment, diastolic blood pressure, systolic blood pressure and improve the situation as well as adverse reactions, serious cases. Results: The total effective rate of clinical treatment in combination therapy group was significantly higher than that in single therapy group (P <0.05). Compared with before treatment, diastolic blood pressure and contractility (P <0.05). The incidence of adverse reactions in the combination therapy group was significantly lower than that of the single therapy group (P <0.05) The incidence of adverse reactions in combination therapy group was 16.3%. The incidence of adverse reactions in combination therapy group was significantly lower than that in the single therapy group (P <0.05). At the same time, there was no significant difference between the two groups (P> 0.05). Conclusion Telmisartan and amlodipine besylate combined with telbivudine alone can be used to treat patients with essential hypertension to improve clinical symptoms and blood pressure levels without serious adverse reactions appear.